Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371873 | 0.90 | DGAT1 (0.39) | JAK2JAK3JAK1DGAT1KLKB1 | |
| SCHEMBL29936388 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL1370337 | 0.85 | DGAT1 (0.38) | JAK2JAK3JAK1DGAT1MAPT | |
| SCHEMBL14751074 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL29936175 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL29936386 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL18210148 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL18210150 | 0.85 | HCAR2 (0.40) | JAK3DGAT1 | |
| SCHEMBL14750993 | 0.85 | JAK1 (0.33) | JAK2JAK3JAK1DGAT1SMYD3 | |
| SCHEMBL12145968 | 0.85 | DGAT1 (0.38) | JAK2JAK3JAK1DGAT1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011144585-A1 | PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK2 3/4885JAK3 7/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.